4//SEC Filing
Quiroga Cortes Isidoro Alfonso 4
Accession 0001104659-22-114089
CIK 0001856725other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 7:41 PM ET
Size
10.2 KB
Accession
0001104659-22-114089
Insider Transaction Report
Form 4
Quiroga Cortes Isidoro Alfonso
10% Owner
Transactions
- Purchase
Class A Common Stock
2022-10-31$6.11/sh+16,523$100,977→ 5,218,821 total(indirect: By Partnership) - Purchase
Class A Common Stock
2022-11-02$6.31/sh+25,197$158,955→ 5,247,786 total(indirect: By Partnership) - Purchase
Class A Common Stock
2022-11-01$5.98/sh+3,768$22,533→ 5,222,589 total(indirect: By Partnership)
Footnotes (4)
- [F1]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.98 to $6.14 per share, inclusive. The reporting persons undertake to provide Rani Therapeutics Holdings, Inc., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.96 to $6.22 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.50 per share, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]Isidoro Alfonso Quiroga Cortes directly owns 100% of the issued and outstanding interest of the Aequanimitas Management LLC (the "General Partner"). The General Partner directly controls Aequanimitas Limited Partnership ("Aequanimitas") as its general partner with the power to manage Aequanimitas. Quiroga Cortes is the sole limited partner of Aequanimitas.
Documents
Issuer
Rani Therapeutics Holdings, Inc.
CIK 0001856725
Entity typeother
Related Parties
1- filerCIK 0001854578
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 7:41 PM ET
- Size
- 10.2 KB